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Abstract
Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing
schizophrenia. The behavioural profiles of the psychotropic cannabis constituent D9-tetrahydrocannabinol
(D9-THC) and the non-psychotomimetic constituent cannabidiol (CBD) were investigated with a battery of
behavioural tests relevant to anxiety and positive, negative and cognitive symptoms of schizophrenia.
Male adult C57BL/6JArc mice were given 21 daily intraperitoneal injections of vehicle, D9-THC (0.3, 1,
3 or 10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg). D9-THC produced the classic cannabinoid CB1 receptor-
mediated tetrad of hypolocomotion, analgesia, catalepsy and hypothermia while CBD had modest
hyperthermic effects. While sedative at this dose, D9-THC (10 mg/kg) produced locomotor-independent
anxiogenic effects in the open-field and light–dark tests. Chronic CBD produced moderate anxiolytic-like
effects in the open-field test at 50 mg/kg and in the light–dark test at a low dose (1 mg/kg). Acute and
chronic D9-THC (10 mg/kg) decreased the startle response while CBD had no effect. Prepulse inhibition
was increased by acute treatment with D9-THC (0.3, 3 and 10 mg/kg) or CBD (1, 5 and 50 mg/kg) and
by chronic CBD (1 mg/kg). Chronic CBD (50 mg/kg) attenuated dexamphetamine (5 mg/kg)-induced
hyperlocomotion, suggesting an antipsychotic-like action for this cannabinoid. Chronic D9-THC decreased
locomotor activity before and after dexamphetamine administration suggesting functional antagonism of
the locomotor stimulant effect. These data provide the first evidence of anxiolytic- and antipsychotic-like
effects of chronic but not acute CBD in C57BL/6JArc mice, extending findings from acute studies in other
inbred mouse strains and rats.
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Introduction
The population risk for schizophrenia is increased by
cannabis use (Henquet et al. 2005 ; Moore et al. 2007).
This increase is reported to be greater in people with
a predisposition to psychosis (Henquet et al. 2005).
D9-tetrahydrocannabinol (D9-THC), themost abundant
of the >70 cannabis constituents, produces the
euphoric effects sought by recreational users, and
produces psychotomimetic symptoms such as altered
perception and disrupted working memory. Schizo-
phrenia patients show increased susceptibility to these
effects (D’Souza et al. 2005). D9-THC has partial agonist
efficacy at cannabinoid CB1 and CB2 receptors and
exerts many of its central effects via inhibition of
neurotransmitter release by presynaptic CB1 receptors.
Cannabidiol (CBD), another cannabis constituent,
does not produce the psychotropic effects of D9-THC
and antagonizes the effects of CB1/CB2 receptor
agonists (Pertwee, 2008). Interestingly, consumption of
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cannabis with little or no CBD content is associated
with increased incidence of psychotic symptoms
(Morgan & Curran, 2008; Rottanburg et al. 1982),
suggesting that CBD may partially attenuate the
psychotomimetic effects of D9-THC or other cannabis
constituents. The therapeutic potential for CBD is
supported by observations of its antipsychotic-like
(Leweke et al. 2000 ; Zuardi et al. 2006a) and anxiolytic-
like effects (Crippa et al. 2004, 2009) after acute oral
administration in healthy volunteers. While prelimi-
nary data in treatment-resistant schizophrenia patients
suggest that CBDmonotherapy is not effective (Zuardi
et al. 2006b), regular oral CBD administration reduces
psychotic symptoms in Parkinson’s disease sufferers
(Zuardi et al. 2008).
Reports of CBD effects in rodents are currently re-
stricted to acute studies : CBD exerts anxiolytic-like
(Campos & Guimaraes, 2008 ; Guimaraes et al. 1994;
Moreira et al. 2006 ; Onaivi et al. 1990 ; Resstel et al.
2006) and antipsychotic-like (Long et al. 2006; Moreira
& Guimaraes, 2005 ; Zuardi et al. 1991) effects in mice
(Swiss, ICR) and rats (Wistar). Interestingly, CBD in-
duces c-fos expression in the rat nucleus accumbens
but not the dorsal striatum, in a pattern similar to that
of clozapine (Guimaraes et al. 2004). To accurately
model the effects of regular cannabis use in humans
and to determine the potential for lasting clinical
efficacy of cannabinoids such as CBD, chronic rodent
behavioural studies are necessary. Furthermore, since
a majority of mutant mouse models are generated
on a C57BL/6J or mixed C57BL/6Jr129SvJ genetic
background, studies in C57BL/6J mice are crucial for
further research.
This study therefore aimed to directly compare the
acute and chronic effects of D9-THC and CBD in
C57BL/6J mice using a multi-tiered battery of schizo-
phrenia- and anxiety-relevant behavioural tests. CBD
effects were compared to the well-characterized effects
of D9-THC in the classic cannabinoid CB1 receptor
agonist ‘ tetrad’. Following this, mice were assessed
using a comprehensive multi-tiered battery of behav-
ioural models relevant to positive (spontaneous hyper-
activity), negative (social withdrawal, anxiety) and
cognitive (disrupted learning and working memory,
impaired sensorimotor gating) symptoms of schizo-
phrenia during repeated treatment with D9-THC or
CBD. The antipsychotic effect of chronic CBD on drug-
induced psychotomimetic behaviour was assessed
using acute challenges with the non-competitive
NMDA antagonist MK-801 and the catecholaminergic
stimulant dexamphetamine (Dex). To enable com-
parison of the effects of repeated treatment, a follow-
up study on acute anxiolytic and potentially anti-
psychotic-like effects of CBD was conducted, using
doses that were behaviourally active in the chronic
study.
Methods
Animals
Test animals were 119 male C57BL/6JArc mice (aged
12–14 wk). Standard social interaction opponents
were 12 male A/JArc mice (aged 9–10 wk) (Animal
Resources Centre, Australia). Mice were maintained
under a 12-h light/red light cycle (lights on 07:00
hours) and pair-housed in Macrolon cages (1144B:
Tecniplast, Australia) containing paper tissues
(Kimwipes1, Kimberley-Clark, Australia) as nesting
material with ad libitum access to water and standard
irradiated mouse feed (Gordon’s Specialty Stockfeeds,
Australia). Chronic experiments were performed in
four sets of 22–24 mice over 8 wk, with treatment ran-
domized and counterbalanced across sets. Follow-up
acute experiments with CBD were performed in a
single set of 29 mice. Research and animal care pro-
cedures were approved by the Garvan Institute/
St Vincent’s Hospital Animal Experimentation Ethics
Committee in accordance with the Australian Code of
Practice for the Care and Use of Animals for Scientific
Purposes.
Drug treatment
D9-THC and CBD (THC Pharm GmbH, Germany)
were suspended in a 1:1 :18 mixture of ethanol :
Tween-80 :saline. Dex and MK-801 (Sigma, Australia)
were dissolved in saline. Dose ranges of D9-THC and
CBD were based on previous studies (Boucher et al.
2007 ; Long et al. 2006). Drugs were injected at a vol-
ume of 10 ml/kg.
For chronic treatment, mice received 21 consecu-
tive daily intraperitoneal (i.p.) injections of vehicle
(1 :1 :18 ethanol :Tween-80 :saline), D9-THC (0.3, 1, 3 or
10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg) (n=10). On
day 7 all mice were injected with MK-801 (0.5 mg/kg
i.p.) 35 min after cannabinoid injection. On day 21 all
mice were injected with Dex (5 mg/kg i.p.) 45 min
after cannabinoid injection.
Follow-up experiment
After observing key effects of chronic CBD we in-
vestigated the acute behavioural effects of CBD at rel-
evant doses. Separate groups of age-matched male
C57BL/6JArc mice received an i.p. injection of vehicle
or CBD (1 or 50 mg/kg) (n=9–10). Mice were tested in
the elevated plus maze (EPM) (5 min) followed by
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open-field (OF) testing of Dex-induced locomotor
activity (45 min), in which all mice received an injec-
tion of Dex (5 mg/kg i.p.) 45 min after vehicle or CBD
injection (in a manner identical to the Dex-induced OF
testing after chronic CBD).
Behavioural testing
Injections commenced at the start of the light cycle
(07:00 hours). On behavioural testing days injections
were staggered within the light cycle to standardize
intervals between injection and testing (Table 1). Mice
were returned to the home cage following injection
and behavioural testing. Environmental odours were
removed from test apparatus between trials with 70%
ethanol.
In conducting behavioural testing for schizo-
phrenia, experiments need to target the range of be-
havioural domains that are affected in the disorder
(Powell & Miyakawa, 2006). Furthermore, behavioural
testing batteries over one or more days have pre-
viously yielded informative data on anxiety-related
behaviour (Karl et al. 2008), sensory and motor func-
tion (Metz & Schwab, 2004) and defensive behaviour
(Griebel et al. 1999). Ethical considerations prompted
us to investigate more than one behavioural domain in
each group of mice, and during repeated treatment,
the order of behavioural testing proceeded from least
to most aversive, such that tests involving an aversive
stimulus (i.e. electric footshock in passive avoidance)
were performed after tests of anxiety-like behaviour
such as the EPM to avoid confounds related to the
stress response of the mice.
Cannabinoid tetrad A: body temperature, catalepsy
and nociception
Mice were assessed for the classical cannabinoid be-
havioural tetrad of hypothermia, catalepsy, hypoloco-
motion and nociception (Compton et al. 1993). Body
temperature was measured 5 min before and 30 min
after injection on days 1, 3, 5, 7, 12 and 14 using a lu-
bricated rectal thermometer (SDR Clinical Technology,
Australia). Catalepsy was measured 20 min after in-
jection on days 1, 3, 5, 7, 12 and 14. The hindpaws of the
mouse were placed on the bench and the forepaws
were placed on a bar (0.2 cm diameter) raised 8 cm off
the bench surface. The latency for the mouse to place
both forepaws on the benchwas recorded. Nociception
was measured with the hot-water tail-flick test 45 min
after injection on days 1, 14 and 20. Mice were gently
wrapped in a towel leaving the tail unrestrained. The
tail tip (1.5 cm) was placed in a beaker of water at room
temperature (25 xC) for 10 s then placed immediately
in a water bath at 52 xC. The latency for the mouse to
flick its tail was recorded. Data are reported as the
mean of three consecutive trials performed for each
mouse, with 2-min inter-trial intervals during which
mice were returned to the home cage.
Cannabinoid tetrad B: spontaneous and Dex-induced
locomotor activity
Locomotor activity was measured by placing mice into
an OF activity chamber (Med Associates Inc., USA).
Horizontal (distance travelled) and vertical activity
Table 1. Chronic test biography of C57BL/6JArc mice
Day Test Time
x2 Prepulse inhibition acclimatization 07:00–10:00
16:00–19:00
x1 Prepulse inhibition acclimatization 07:00–10:00
16:00–19:00
0 Prepulse inhibition (baseline) 07:00–10:00
16:00–19:00
1 Body temperature, catalepsy, open field,
tail flick, prepulse inhibition
07:00–11:00
15:00–19:00
3 Body temperature, catalepsy 07:00–10:00
5 Body temperature, catalepsy 07:00–10:00
7 Body temperature, catalepsy, MK-801
and prepulse inhibition
07:00–11:00
15:00–19:00
12 Body temperature, catalepsy 07:00–10:00
14 Body temperature, catalepsy, tail flick 07:00–10:00
15 Open field 07:00–10:00
16 Y-maze 07:00–12:00
17 Light–dark, elevated plus maze 07:00–13:00
18 Social interaction, prepulse inhibition 07:00–11:00
15:00–19:00
19 Passive avoidance training 07:00–11:00
20 Passive avoidance retention test, tail flick 07:00–11:00
21 Dex and open field 07:00–15:00
D9-THC, D9-tetrahydrocannabinol ; CBD cannabidiol, Dex,
dexamphetamine.
Ninety mice were tested over a period of 8 wk. Mice were
injected with either vehicle or D9-THC (0.3, 1, 3 or 10 mg/kg
body weight) or CBD (1, 5, 10 or 50 mg/kg) once daily for
21 d (n=10). On day 7, all mice were injected with MK-801
(0.5 mg/kg) and on day 21 all mice were injected with
Dex (5 mg/kg). The test schedule shows the order in which
tests were completed. Test order and age at commencement
of testing was standardized to avoid differential impact
of repeated testing on the behavioural parameters
investigated. Tests involving an aversive stimulus
(i.e. electric footshock in passive avoidance) were
performed after tests of anxiety-like behaviour such as the
elevated plus maze to avoid confounds related to the stress
response of the mice.
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(rearing) in central and peripheral zones were
measured (described previously ; Karl et al. 2007). The
ratio of central to total distance travelled (distance
ratio) and time spent in the central zone were taken as
measures of anxiety (Denenberg, 1969). On days 1 and
15 mice were placed in the OF 35 min after injection
and allowed to explore freely for 10 min. On day 21 of
the chronic study, and in the follow-up study, mice
were placed in the OF 30 min after injection and
allowed to explore freely for 15 min before they were
removed, injected with Dex and immediately returned
to the chamber for a further 30 min.
Light–dark (LD) test
Mice were placed into the opening of the dark com-
partment of the LD test apparatus (described pre-
viously ; Karl et al. 2007) and allowed to explore freely
for 10 min. The ratio of distance travelled in the light
compartment to total distance travelled (distance ratio)
and time spent in the light compartment were taken
as measures of anxiety. Mice were tested with the LD
test 30 min after injection on day 17.
EPM
Mice were placed onto the central platform of the EPM
(described previously ; Karl et al. 2007) facing an en-
closed arm and allowed to explore freely for 5 min.
Arm entries, time spent in arms and in the central
platform, rearing and head dipping were scored.
Arm entries were recorded whenmice entered the arm
with all four paws. Anxiety-related behaviour was
measured by entries into the open arm from the centre,
percentage of time spent on open arms (divided into
inner and outer halves) and the percentage of open-
arm entries (open-arm entry ratio) (Hogg, 1996;
Pellow et al. 1985). Mice were tested in the EPM 45 min
after injection on day 17 and 25 min after injection in
the acute study.
Social interaction (SI)
SI between pairs of rodents is used to measure anxiety-
like behaviours (File & Seth, 2003 ; Kask et al. 2001).
Furthermore, reduction in SI models aspects of
social withdrawal observed in schizophrenia patients
(Ellenbroek & Cools, 2000 ; Rung et al. 2005). Test mice
and weight-matched A/JArc standard opponents,
with no prior exposure to either the test arena or to
each other, were placed in opposite corners of a grey
perspex arena (35r35r30 cm; illumination 50 lx) and
allowed to explore freely for 10 min. Frequency and
total duration of the active socio-positive behaviours
general sniffing, anogenital sniffing, allogrooming,
following and climbing over/under in each test mouse
were recorded manually. Mice were tested for SI
35 min after injection on day 18.
Prepulse inhibition (PPI)
PPI, an operational measure of sensorimotor gating, is
impaired in schizophrenia patients (Braff et al. 2001;
Ludewig et al. 2003). Startle reactivity was measured
using SR-Lab startle chambers (San Diego Instru-
ments, USA). Mice were habituated to this apparatus
for 30 min on two consecutive days. The next day,
mice were tested for baseline PPI, and on the following
day chronic drug treatment began. PPI testing com-
menced 60 min after injection on days 1 and 18 and
55 min after injection on day 7 (20 min after injection
of MK-801). PPI test sessions consisted of 5-min ac-
climatization to 70-dB background noise followed
by 105 trials presented in a pseudo-random order :
5r70-dB trials (background) ; 5r80-dB trials ; 5r
100-dB trials ; 15r120-dB trials (startle) and 15 sets of
five trials comprising a prepulse of either 74, 82 or
86 dB presented 32, 64, 128, 256 or 512 ms prior to a
startling pulse of 120 dB (PPI response). Inter-trial
intervals varied randomly from 10 s to 20 s. Responses
to each trial were calculated as average mean ampli-
tudes detected by the accelerometer. Percentage PPI
(% PPI) was calculated as
startle response (120 dB)xPPI response
startle response (120 dB)
r100:
% PPI was averaged across inter-stimulus (prepulse-
startling pulse) intervals to produce a mean % PPI for
each prepulse intensity.
Y-maze
The natural tendency of mice to alternate successive
entry choices of arms in a Y-maze (spontaneous alter-
nation) is used as an assessment of memory retention
(Hughes, 2004). Mice were placed into the centre of a
grey perspex Y-shaped maze (30 cmr10 cmr17 cm,
arms joined by a triangular centre section) and al-
lowed to explore freely for 8 min. Different patterns on
each armwall provided intra-maze directionality cues.
Objects (e.g. a camera tripod) at the end of each arm
provided extra-maze directionality cues. Arm entries
(defined when all four paws were inside the arm) were
recorded manually. The spontaneous alternation score
was calculated as the number of novel triplet entries
(three consecutive entries into different arms) ex-
pressed as a percentage of the maximum possible
triplet entries (Hodges, 1996). Mice were tested 30 min
after injection on day 16.
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Passive avoidance (PA)
In PA, memory retention is indicated by avoidance of
a naturally less aversive dark compartment after it is
paired with an electrical footshock (Bovet et al. 1969).
This hippocampus-dependent learning test is influ-
enced by fear of highly illuminated areas and aversive
stimuli (e.g. electrical footshock), and by nociception.
Training and retention trials were performed 30 min
after injection on days 19 and 20, respectively, using a
shuttle box system (TSE Systems, Bad Homburg,
Germany). Latency to enter the dark chamber on each
trial was measured (cut-off time: 300 s) (previously
described; Karl et al. 2008). Increased latency in the
retention trial indicated memory of the aversive
stimulus (0.4 mA footshock; 2 s). Due to apparatus
malfunction several mice did not receive a footshock
and were excluded from further analysis.
Statistical analysis
In analyses for all experiments the vehicle group was
compared separately to the D9-THC (THC 0.3, THC 1,
THC 3 and THC 10) and CBD (CBD 1, CBD 5, CBD 10
and CBD 50) groups. Differences between treatment
groups were analysed with one-way (factor : treat-
ment) or repeated-measures analyses of variance
(ANOVA) [factors : treatment, 5-min block (Dex-
induced locomotor activity), prepulse intensity and
trial (PA)]. Main and interaction effects were identified
when p<0.05. Planned contrasts were used to de-
termine which treatment groups were significantly
different to vehicle (simple contrasts), to locate differ-
ences between levels of within-subjects factors (poly-
nomial contrasts) and to locate interactions between
levels of treatment groups and within-subjects factors
(special interaction contrasts). Huynh–Feldt correc-
tions for non-sphericity were applied. Degrees of
freedom, F values and p values from ANOVA are
presented in the Results, and p values from planned
contrasts are indicated in the Figures and Tables by
asterisks (* p<0.05, ** p<0.01, *** p<0.001). Data are
presented as mean¡standard error of the mean
(S.E.M.). Analysis was performed using SPSS 16.0 for
Windows (SPSS Inc., USA).
Results
Cannabinoid tetrad A: body temperature, catalepsy
and nociception
Acute D9-THC (10 mg/kg) produced significant hypo-
thermia [one-way ANOVA: F(4, 49)=9.3, p<0.001]
and catalepsy [one-way ANOVA: F(4, 43)=6.0, p<
0.001] (Table 2). There was a trend towards an effect of
acute D9-THC on nociception (one-way ANOVA:
p=0.08). D9-THC (10 mg/kg) had a significant anti-
nociceptive effect on day 14 [one-way ANOVA:
F(4, 44)=3.9, p=0.01] (Table 2), but not on day 20.
CBD (1 and 10 mg/kg) induced a hyperthermic
response on day 7 [one-way ANOVA: F(4, 49)=3.5,
p<0.05] but had no effect on catalepsy or nociception
(Table 2).
Cannabinoid tetrad B: spontaneous
locomotor activity
D9-THC decreased overall distance travelled on day 1
[one-way ANOVA: F(4, 49)=3.5, p<0.05] and day 15
[F(4, 46)=3.6, p<0.05] at 10 mg/kg and on day 21
[F(4, 44)=13.3, p<0.001] at 1, 3 and 10 mg/kg (Fig. 1a).
D9-THC also decreased peripheral distance travelled
in the OF test on day 1 [one-way ANOVA: F(4, 49)=
3.1, p<0.05] at 10 mg/kg and on day 21 [F(4, 44)=12.8,
p<0.001] at 1, 3 and 10 mg/kg (Fig. 1b). D9-THC also
decreased the total distance travelled in the LD test
[one-wayANOVA:F(4, 46)=9.6,p<0.001]at10 mg/kg
(Fig. 1c) and the total number of arm entries in the
EPM [one-way ANOVA: F(4, 42)=4.0, p<0.01] at 3
and 10 mg/kg (Fig. 1d), confirming its locomotor
suppressant effects.
In contrast, CBD had no effect on any locomotor
activity measure in the OF test (one-way ANOVA:
p>0.05 ; Fig. 1e, f). CBD (10 mg/kg) significantly
decreased the total distance travelled in the LD test
[one-way ANOVA: F(4, 44)=2.6, p<0.05] (Fig. 1g).
There was a trend towards an effect of CBD on the
total number of EPM arm entries (one-way ANOVA:
p=0.06 ; Fig. 1h).
Dex-induced locomotor activity
Chronic
There were main effects of chronic D9-THC (repeated-
measures ANOVA: F(4, 38)=4.6, p<0.01) and time
(5-min block) [F(2.6, 97.8)=196.2, p<0.001] on the
distance travelled in the OF test on day 21, and a
moderate trend towards an interaction ofD9-THCwith
time (p=0.09) (Fig. 2a). An interaction contrast be-
tween the 15-min baseline (BL) and 30-min post-Dex
periods showed that Dex increased the distance trav-
elled in all D9-THC-treated groups [BLrpost-Dex:
F(1, 38)=284.7, p<0.001]. The magnitude of this in-
crease was dependent on D9-THC dose [BLrpost-
DexrD9-THC interaction : F(4, 38)=2.8, p<0.05].
Doses and time-points at which D9-THC attenuated
the Dex-induced increase in locomotor activity were
determined by special interaction contrasts (BLr
specific post-Dex time-pointrD9-THC) (Fig. 2a).
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Table 2. Body temperature, catalepsy and nociception
Parameter Day Vehicle D9-THC 0.3 D9-THC 1 D9-THC 3 D9-THC 10 CBD 1 CBD 5 CBD 10 CBD 50
Thermic response :
difference in body
temperature measured
5 min before and 30 min
after injection (D xC)
1 1.4¡0.3 2.3¡0.3 2.3¡0.4 1.2¡0.4 x1.8¡1.0* 1.5¡0.7 1.4¡0.3 2.2¡0.5 2.2¡0.5
3 1.4¡0.3 1.3¡0.3 1.6¡0.1 1.5¡0.2 0.8¡0.4 1.7¡0.3 1.0¡0.2 1.2¡0.3 1.4¡0.1
5 1.2¡0.3 1.1¡0.5 1.2¡0.2 1.4¡0.3 1.5¡0.2 1.8¡0.3 1.2¡0.3 1.2¡0.3 1.5¡0.2
7 0.9¡0.4 1.6¡0.3 1.0¡0.2 1.7¡0.2 1.6¡0.3 2.0¡0.2** 1.0¡0.3 1.8¡0.3* 1.1¡0.2
12 1.6¡0.2 1.0¡0.3 0.8¡0.4 1.4¡0.3 1.3¡0.2 0.8¡0.2 1.3¡0.2 1.6¡0.4 1.1¡0.2
14 1.8¡0.4 1.1¡0.2 1.4¡0.4 1.9¡0.4 1.3¡0.1 1.6¡0.3 1.2¡0.4 1.2¡0.2 1.4¡0.2
Catalepsy : latency to
remove both forepaws
from bar and place on
bench, 20 min after
injection (ms)
1 58.7¡5.2 71.4¡6.8 68.9¡6.8 93.9¡11.4 390.5¡137.9* 50.4¡4.5 114.8¡40.3 64.0¡11.3 55.4¡11.3
3 48.3¡6.5 44.7¡5.3 70.3¡14.3 48.3¡6.2 66.1¡8.2 46.9¡5.9 76.6¡17.3 39.6¡2.1 59.5¡7.8
5 44.9¡3.1 43.7¡4.3 85.4¡32.4 53.7¡4.9 57.2¡5.1 37.4¡1.9 41.2¡2.9 38.9¡3.6 47.9¡5.6
7 49.7¡8.0 45.8¡12.7 49.5¡5.9 53.9¡10.1 45.1¡4.8 41.7¡4.5 40.4¡4.6 38.4¡2.2 42.7¡5.7
12 39.4¡1.2 69.0¡34.1 56.7¡12.2 51.3¡5.6 63.9¡10.6 42.1¡7.0 54.3¡4.2 38.3¡2.4 79.0¡22.2
14 36.6¡1.0 43.2¡5.4 56.3¡13.2 62.0¡6.8 56.1¡6.4 38.9¡4.7 49.3¡6.7 38.8¡2.8 49.5¡7.1
Nociception : mean latency
to flick tail immersed in
52 xC water, 45 min after
injection (s), measured
over three consecutive
trials
1 2.4¡0.1 2.6¡0.2 2.6¡0.2 2.9¡0.3 3.5¡0.4 2.3¡0.1 2.0¡0.2 2.4¡0.2 2.2¡0.1
14 2.6¡0.3 3.1¡0.4 3.0¡0.2 2.9¡0.2 3.8¡0.2*** 3.0¡0.3 2.5¡0.2 2.5¡0.3 2.4¡0.2
20 2.5¡0.3 2.4¡0.3 2.5¡0.3 2.5¡0.3 3.1¡0.3 2.5¡0.2 2.3¡0.3 2.3¡0.3 1.8¡0.1
D9-THC, D9-tetrahydrocannabinol ; CBD, cannabidiol.
Body temperature, catalepsy and nociception after injection with D9-THC (0.3, 1, 3 or 10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg) on various days of treatment.
Data represent mean (¡S.E.M.), n=8–10.
* p<0.05, ** p<0.01, *** p<0.001 vs. vehicle group (one-way ANOVA and planned contrasts).
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There was a main effect of time (5-min block), but
not CBD, on distance travelled in the OF on day 21
[repeated-measures ANOVA: F(2.2, 92.9)=225.8, p<
0.001] (Fig. 2b). There was no CBDrtime interaction
(p>0.05). An interaction contrast showed that Dex in-
creased the distance travelled in all CBD-treated groups
[BLrpost-Dex: F(1, 42)=330.1, p<0.001]. The magni-
tude of this increase was independent of CBD dose
(BLrpost-DexrCBD interaction contrast : p>0.05).
Special interaction contrasts (BLrspecific post-Dex
time-pointrCBD) showed that CBD (50 mg/kg)
attenuated the Dex-induced increase in locomotor
activity at 35–40 min and 40–45 min (Fig. 2b).
Acute CBD
In the follow-up experiment investigating the effect of
acute CBD on Dex-induced locomotor activity there
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Fig. 1. Measures of locomotor activity after injection of D9-tetrahydrocannabinol (THC) (0.3, 1, 3 or 10 mg/kg) or cannabidiol
(CBD) (1, 5, 10 or 50 mg/kg). (a, e). Total distance travelled (open-field test, 10 min) on days 1, 15 and 21 of treatment. (b, f)
Distance travelled in the peripheral area (open-field test). (c, g) Distance travelled (light-dark test, 10 min) on day 17. (d, h)
Frequency of entries into open and closed arms (elevated plus maze, 5 min) on day 17. Data represent mean¡S.E.M. (n=10).
* p<0.05, ** p<0.01, *** p<0.001 vs. vehicle (one-way ANOVA and planned contrasts).
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was amain effect of time (5-min block), but not CBD, on
distance travelled in the OF test [repeated-measures
ANOVA: F(2.7, 71.1)=112.0, p<0.001] (Fig. 3). There
was no CBDrtime interaction (p>0.05). Within-
subjects contrasts showed that Dex increased the
distance travelled in all CBD-treated groups [BL vs.
post-Dex: F(1, 26)=211.6, p<0.001]. The magnitude
of this increase was independent of CBD dose (BL vs.
post-DexrCBD interaction contrast : p>0.05). Special
interaction contrasts (BL vs. specific post-Dex time-
pointrCBD vs. vehicle) showed that CBD did not
affect the Dex-induced increase in locomotor activity
at any time-point (p>0.05).
Exploratory activity
Vertical activity in the OF test was decreased by
D9-THC (1, 3 and 10 mg/kg) on day 1 [one-way
ANOVA: F(4, 49)=8.2, p<0.001] and day 15
[F(4, 46)=7.9, p<0.001] and by D9-THC (3 and
10 mg/kg) on day 21 [F(4, 44)=8.4, p<0.001]
(Table 3). This was confirmed by significant inhibition
by D9-THC (10 mg/kg) of rearing in the LD test [one-
way ANOVA: F(4, 46)=3.5, p<0.05 ; data not shown]
and rearing [one-way ANOVA: F(4, 42)=4.7, p<0.01]
and head dipping [one-way ANOVA: F(4, 42)=3.1,
p<0.05] in the EPM (Table 3).
CBD did not affect vertical activity/rearing in the
OF, LD or EPM tests (one-way ANOVA: p>0.05).
There was a trend towards an effect of CBD on head
dipping in the EPM (one-way ANOVA: p=0.06)
(Table 3).
Anxiety measures
Chronic
D9-THC (10 mg/kg) significantly decreased the time
spent in the central zone of the OF test on day 15 [one-
way ANOVA: F(4, 46)=2.8, p<0.05] and day 21
[F(4, 44)=3.4, p<0.05] (Fig. 4a) and decreased the
distance ratio on day 1 [F(4, 49)=3.9, p<0.01], day 15
[F(4, 46)=3.1, p<0.05] and day 21 [F(4, 44)=8.6,
p<0.001] (Fig. 4b). Similarly, D9-THC (10 mg/kg) de-
creased the time spent in the light compartment [one-
way ANOVA: F(4, 46)=3.5, p<0.05] and the distance
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Fig. 2. Total distance travelled over time (open-field test, 45 min) after injection of (a) D9-tetrahydrocannabinol (THC) (0.3, 1,
3 or 10 mg/kg) or (b) cannabidiol (CBD) (1, 5, 10 or 50 mg/kg) during baseline (BL) and after injection of 5 mg/kg Dex
(post-Dex) on day 21 of treatment. Data represent mean¡S.E.M. (n=7–10). # p<0.05 (D9-THC 0.3 vs. vehicle) ; + p<0.05
(D9-THC 1 vs. vehicle) ; # p<0.05, ## p<0.01 (D9-THC 3 vs. vehicle) ; * p<0.05, ** p<0.01, *** p<0.001 (D9-THC 10 or CBD 50
vs. vehicle) (repeated-measures ANOVA and planned contrasts).
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Fig. 3. Total distance travelled over time (open-field test,
45 min) after a single injection of cannabidiol (CBD) (1 or
50 mg/kg) during baseline (BL) and after injection of
5 mg/kg Dex (post-Dex). Data represent mean¡S.E.M.
(n=9–10).
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ratio [one-way ANOVA: F(4, 46)=2.8, p<0.05] in the
LD test (Fig. 4c, d). There was a trend towards an effect
of D9-THC on time spent in the inner open arm in the
EPM (one-way ANOVA: p=0.08), but no effect on the
open-arm entry ratio (data not shown).
In contrast, CBD (50 mg/kg) increased the time
spent in the central zone of the OF test on day 15 [one-
way ANOVA: F(4, 48)=3.5, P<0.05] (Fig. 4e). There
was a trend towards a significant effect of CBD on the
distance ratio on day 15 (one-way ANOVA: p=0.07)
(Fig. 4 f). In the LD test, CBD (1 mg/kg) significantly
increased the time spent in the light compartment
[one-way ANOVA: F(4, 44)=3.0, p<0.05] and the dis-
tance ratio [F(4, 44)=2.8, p<0.05] (Fig. 4g, h). There
was a moderate trend towards an effect of CBD on
time spent in the inner open arm in the EPM (one-way
ANOVA: p=0.09), but no effect on the open-arm entry
ratio or percentage of time spent on open arms (data
not shown).
Acute CBD
In the follow-up experiment investigating the effect of
CBD in the EPM there was no effect of CBD on total
number of EPM arm entries, percentage time in the
open arms, ratio of open-arm entries to total arm
entries, time in the centre zone, head dipping, or
rearing (one-way ANOVA: p>0.05 ; data not shown).
Startle response and PPI
All mice displayed identical startle response and PPI
at baseline testing 1 d prior to the first injection (data
not shown). There was a main effect of prepulse in-
tensity on PPI (p<0.001) and a significant linear con-
trast between levels of prepulse intensity (p<0.001) on
all test days, indicating that PPI increased with in-
creasing prepulse intensity.
D9-THC (10 mg/kg) decreased the startle response
on day 1 [one-way ANOVA: F(4, 48)=3.1, p<0.05]
and day 18 [F(4, 44)=3.1, p<0.05] (Table 4). There was
no effect of D9-THC on the startle response when mice
were treated with MK-801 (data not shown).
There was no effect of CBD on startle response
on any day (one-way ANOVA: p>0.05). There was
no main effect of D9-THC on PPI on days 1, 7 or 18
(repeated-measures ANOVA: p>0.05, data not shown
for day 7) (Fig. 5a, b). There was a significant interac-
tion between D9-THC and prepulse intensity on day 1
[F(6.5, 71.4)=5.0, p<0.001] and day 18 [F(7.0, 70.2)=
5.6, p<0.001]. Planned contrasts showed that acute
D9-THC (0.3, 3 and 10 mg/kg) significantly increased
PPI (Fig. 5a).
There was a main effect of CBD on PPI on day 1
[repeated-measures ANOVA: F(4, 44)=4.9, p<0.01]Ta
b
le
3.
E
x
p
lo
ra
to
ry
ac
ti
v
it
y
P
ar
am
et
er
D
ay
V
eh
ic
le
D
9 -
T
H
C
0.
3
D
9 -
T
H
C
1
D
9 -
T
H
C
3
D
9 -
T
H
C
10
C
B
D
1
C
B
D
5
C
B
D
10
C
B
D
50
V
er
ti
ca
l
ac
ti
v
it
y
(O
F
)
(n
)
1
10
7.
9¡
6.
0
75
.8
¡
7.
4
67
.8
¡
9.
9*
29
.9
¡
13
.2
**
*
32
.4
¡
16
.9
**
*
10
4.
7¡
17
.0
11
1.
9¡
11
.5
88
.0
¡
10
.5
93
.2
¡
7.
3
15
62
.9
¡
7.
6
53
.9
¡
5.
8
45
.4
¡
5.
9*
38
.5
¡
5.
1*
*
19
.1
¡
4.
3*
**
67
.9
¡
9.
6
75
.9
¡
8.
8
53
.3
¡
6.
3
82
.3
¡
10
.6
21
68
.3
¡
7.
6
61
.6
¡
7.
0
55
.3
¡
15
.5
35
.3
¡
6.
7*
*
4.
3¡
1.
7*
**
79
.6
¡
9.
3
63
.8
¡
7.
9
63
.0
¡
6.
2
69
.9
¡
10
.7
R
ea
ri
n
g
(E
P
M
)
(n
)
17
11
.2
¡
2.
0
12
.0
¡
1.
7
12
.1
¡
2.
1
7.
4¡
2.
4
2.
8¡
1.
1*
*
12
.3
¡
2.
2
12
.3
¡
1.
8
13
.4
¡
1.
4
15
.5
¡
1.
2
H
ea
d
d
ip
p
in
g
(E
P
M
)
(n
)
17
13
.1
¡
1.
5
12
.2
¡
1.
5
9.
9¡
1.
9
9.
7¡
2.
7
4.
3¡
1.
5*
*
12
.4
¡
2.
8
10
.5
¡
0.
9
12
.0
¡
1.
3
17
.6
¡
2.
0
D
9 -
T
H
C
,
D
9 -
te
tr
ah
y
d
ro
ca
n
n
ab
in
o
l;
C
B
D
,
ca
n
n
ab
id
io
l;
O
F
,
o
p
en
-fi
el
d
;
E
P
M
,
el
ev
at
ed
p
lu
s
m
az
e.
F
re
q
u
en
cy
o
f
v
er
ti
ca
l
ac
ti
v
it
y
(O
F
te
st
,1
0
m
in
)
an
d
re
ar
in
g
an
d
h
ea
d
d
ip
p
in
g
(E
P
M
,5
m
in
)
af
te
r
in
je
ct
io
n
o
f
D
9 -
T
H
C
(0
.3
,1
,3
o
r
10
m
g
/
k
g
)
o
r
C
B
D
(1
,5
,1
0
o
r
50
m
g
/
k
g
)
o
n
v
ar
io
u
s
d
ay
s
o
f
tr
ea
tm
en
t.
D
at
a
re
p
re
se
n
t
m
ea
n
(¡
S
.E
.M
.)
,
n
=
7–
10
.
*
p<
0.
05
,
**
p<
0.
01
,
**
*
p<
0.
00
1
vs
.
v
eh
ic
le
g
ro
u
p
(o
n
e-
w
ay
A
N
O
V
A
an
d
p
la
n
n
ed
co
n
tr
as
ts
).
Behavioural comparison of D9-THC and CBD in mice 869
(Fig. 5c), but not on day 7 (data not shown) or day 18
(p>0.05) (Fig. 5d). There was no CBDrprepulse
intensity interaction (p>0.05). Planned contrasts
showed that acute (1, 5 and 50 mg/kg) (Fig. 5c) and
chronic (1 mg/kg) (Fig. 5d) CBD increased PPI.
Social interaction
D9-THC did not alter total SI time (one-way ANOVA:
p>0.05), but decreased the combined frequency of the
social behaviours general sniffing, anogenital sniffing,
allogrooming, following and climbing over/under
[one-way ANOVA: F(4, 45)=13.2, p<0.001] (Table 5).
D9-THC reduced general sniffing frequency [one-way
ANOVA: F(4, 45)=18.6, p<0.001] at 3 and 10 mg/kg
and its duration [one-way ANOVA: F(4, 45)=3.9,
p<0.01] at 10 mg/kg (Table 5). D9-THC (10 mg/kg)
also decreased anogenital sniffing frequency [one-way
ANOVA: F(4, 45)=4.5, p<0.01].
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Fig. 4. Anxiety-related measures after injection of D9-tetrahydrocannabinol (THC) (0.3, 1, 3 or 10 mg/kg) or cannabidiol (CBD)
(1, 5, 10 or 50 mg/kg). (a, e) Time spent in the central area (open-field test, 10 min) on days 1, 5 and 21 of treatment. (b, f) Distance
ratio (open-field test). (c, g) Time spent in the light compartment (light–dark test, 10 min) on day 17. (d, h) Distance ratio
(light–dark test). Data represent mean¡S.E.M. (n=7–10). * p<0.05, ** p<0.01, *** p<0.001 vs. vehicle group (one-way ANOVA
and planned contrasts).
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There was no effect of CBD on SI (one-way
ANOVA: p>0.05) (Table 5).
Y-maze
There was no effect of treatment on the percentage
of novel entry triplets, indicating equal spontaneous
alternation. Neither D9-THC nor CBD affected the
number of total arm entries (data not shown).
Passive avoidance
A main effect of trial on the latency to enter the
dark chamber in vehicle- and D9-THC-treated mice
[repeated-measures ANOVA: F(1, 26)=31.0, p<0.001]
indicated that all mice learned to avoid the dark
chamber after training (Fig. 6a). There was no main
effect of D9-THC (p>0.05) but there was a significant
D9-THC treatmentrtrial interaction [F(4, 26)=3.4,
Table 4. Startle response
Day Vehicle D9-THC 0.3 D9-THC 1 D9-THC 3 D9-THC 10 CBD 1 CBD 5 CBD 10 CBD 50
1 58.1¡4.0 49.8¡3.4 50.4¡6.2 48.8¡4.3 35.7¡4.6** 44.3¡6.6 57.9¡4.7 52.9¡3.5 52.5¡5.8
18 66.8¡4.9 56.0¡9.0 65.3¡7.9 50.1¡6.0 39.0¡5.2* 54.3¡10.5 71.0¡8.1 64.3¡4.9 65.6¡6.1
D9-THC, D9-tetrahydrocannabinol ; CBD, cannabidiol.
Startle response (arbitrary units) following 120 dB acoustic stimuli [prepulse inhibition (PPI), 30 min] after injection withD9-THC
(0.3, 1, 3 or 10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg) on various days of treatment.
Data represent mean (¡S.E.M.), n=8–10.
* p<0.05, ** p<0.01 vs. vehicle group (one-way ANOVA and planned contrasts).
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Fig. 5. % Prepulse inhibition (PPI) after injection of D9-tetrahydrocannabinol (THC) (0.3, 1, 3 or 10 mg/kg) or cannabidiol
(CBD) (1, 5, 10 or 50 mg/kg) on (a, c) day 1 and (b, d) day 18 of treatment. Data represent mean¡S.E.M. (n=8–10).
* p<0.05, *** p<0.001 vs. vehicle group (repeated-measures ANOVA and planned contrasts).
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p<0.05]. Planned interaction contrasts showed that
D9-THC (10 mg/kg) increased the latency to enter the
dark chamber in the retention trial.
CBD-treated mice also learned to avoid the dark
chamber after training, indicated by a main effect of
trial [repeated-measures ANOVA: F(1, 31)=37.6,
p<0.001] (Fig. 6b). There was no main effect of CBD or
a CBDrtrial interaction.
Discussion
This study is the first to compare acute and
chronic effects of two cannabinoids, the prototypical
psychoactive constituent D9-THC and the non-
psychotomimetic CBD, in a battery of schizophrenia
and anxiety-relevant behavioural tests in male adult
C57BL/6JArc mice. The major findings were : (i) acute
D9-THC and CBD enhanced PPI ; (ii) chronic CBD, but
not D9-THC, enhanced PPI ; (iii) chronic D9-THC and
CBD, but not acute CBD, attenuated Dex-induced
hyperlocomotion and (iv) chronic, but not acute, CBD
produced moderate anxiolytic-like effects.
D9-THC produced the cannabinoid ‘tetrad’ of acute
effects (Compton et al. 1993), consistent with its ac-
cepted profile as a partial CB1 agonist (Pertwee, 2008).
In contrast, CBD had no effect on tetrad measures of
catalepsy, nociception or locomotion and produced
only modest hyperthermia, suggesting that acute CBD
does not produce the sedative or hypolocomotor
effects ofD9-THC in C57BL/6JArc mice (Compton et al.
1992 ; Onaivi et al. 1990 ; Varvel et al. 2006).
Our novel finding that D9-THC (acute) enhanced
PPI in C57BL/6JArc mice adds to an inconclusive
database on the effects of D9-THC on PPI and
represents the first such report of CBD effects. The
results may be species- and strain-dependent since
cannabinoid agonists have previously disrupted PPI
in ddY mice (Nagai et al. 2006) and rats (Schneider &
Koch, 2002), whereas in other animal models, D9-THC
may disrupt (e.g. in socially isolated rats ; Malone &
Taylor, 2006) or enhance PPI (e.g. in neuregulin 1
mutant mice ; Boucher et al. 2007). Importantly, we
observed PPI effects in the absence of changes to the
startle response except with 10 mg/kg D9-THC, which
concomitantly enhanced PPI and decreased the startle
response.
In contrast, few studies exist on the effects of CBD on
PPI, and our findings that acute (1, 5 and 50 mg/kg)
and chronic (1 mg/kg) CBD enhanced PPI represent
the first such report of CBD’s effects. While these
findings do not in themselves represent antipsychotic-
like effects, it is interesting to speculate on whether
such improved baseline sensorimotor gating as thatT
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observed with acute and chronic CBD here might in-
teract with the effect of genetic or pharmacological
challenges on PPI. Previously, CBD alone had no effect
on PPI in Swiss mice but dose-dependently increased
the startle response and reversed an MK-801-induced
PPI deficit at 5 mg/kg (Long et al. 2006). We aimed
to assess whether repeated treatment with CBD
could reverse the effects of MK-801, which dose-
dependently disrupts PPI in rodents (Mansbach &
Geyer, 1989 ; Varty et al. 2001 ; Yee et al. 2004) and mi-
mics the glutamatergic hypofunction thought to occur
in schizophrenia. However, MK-801 did not disrupt
PPI in our vehicle group. Since mice experienced two
PPI sessions prior to testing under MK-801, PPI en-
hancement may have masked its disruptive effect
(Plappert et al. 2006). Future studies will confirm
whether repeated CBD treatment can reverse the
psychotomimetic effect of MK-801 on PPI.
We also investigated the effect of chronic D9-THC or
CBD on the locomotor response to the psychostimu-
lant Dex. Dex produced a typical increase in spon-
taneous locomotor activity that was attenuated in
mice pre-treated with D9-THC (3 or 10 mg/kg) or CBD
(50 mg/kg). D9-THC-treated mice showed decreased
baseline activity, suggesting a functional antagonism
by D9-THC of Dex-induced hyperlocomotion. In con-
trast, CBD attenuated Dex-induced hyperlocomotion
without altering baseline locomotor activity. Import-
antly, acute CBD at low (1 mg/kg) or high (50 mg/kg)
doses did not alter Dex-induced hyperlocomotion.
Although previous studies report that at similar doses
acute CBD reduced Dex- and ketamine-induced
hyperlocomotion (Moreira & Guimaraes, 2005), our
divergent results may be due to genetic differences
between mouse strains used. Further studies may
elucidate potential cumulative effects of CBD on
brain regions associated with the response to the
psychostimulant. Indeed, changes in hypothalamic
c-fos protein expression and catecholamine release
in the nucleus accumbens core following in-
tracerebroventricular CBD administration in rats
(Murillo-Rodriguez et al. 2006) raise intriguing possi-
bilities for mechanisms that may underlie the effects
we observed. Our study is the first to report the effects
of chronic CBD on behaviours related to schizophrenia
and suggests that it might modulate such measures as
PPI and Dex-induced hyperlocomotion.
Another area of therapeutic potential for CBD is in
treating anxiety. We observed that low- and high-dose
chronic CBD produced anxiolytic-like effects, in con-
trast to the anxiogenic effects observed with acute and
chronic D9-THC. The significant effects of D9-THC and
CBD on distance ratios in the OF and LD tests provide
measures of anxiety-related behaviour that are rela-
tively independent of locomotor activity. Interestingly,
acute doses of CBD (1 and 50 mg/kg) that produced
anxiolytic-like effects in the OF and LD tests after
chronic administration had no effect in the EPM. This
contrasts with previous reports of anxiolytic-like
effects of acute CBD (Campos & Guimaraes, 2008 ;
Guimaraes et al. 1994 ; Moreira et al. 2006 ; Onaivi et al.
1990) and may again be due to species and strain
effects (Belzung, 2001). In the SI test, which measures
anxiety and social withdrawal, D9-THC (10 mg/kg)
reduced general sniffing and anogenital sniffing fre-
quency, consistent with reports after high dose (van
Ree et al. 1984) or chronic D9-THC treatment (Quinn
et al. 2008). However, sedation might have reduced the
overall activity of our D9-THC (10 mg/kg)-treated
mice. In contrast, CBD did not alter baseline SI, con-
sistent with previous reports in rats (Malone et al.
2009 ; van Ree et al. 1984). Overall, we provide novel
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evidence that chronic treatment with CBD produces
anxiolytic-like effects in the LD test in C57BL/6JArc
mice.
Learning and working memory are behavioural
domains of therapeutic interest for schizophrenia,
which is marked by cognitive deficits (Elvevag &
Goldberg, 2000). In the present study D9-THC had no
effect on spontaneous alternation or total arm entries
in the Y-maze. Interestingly, D9-THC did not signifi-
cantly reduce the number of arm entries, perhaps due
to the less aversive nature of the Y-maze compared
with the anxiogenic components of the LD or OF
apparatus. In the PA test, D9-THC dose-dependently
increased the latency to enter the aversive stimulus-
paired dark chamber, an unexpected effect since
higher doses of D9-THC generally disrupt short-term
memory (Fadda et al. 2004; Quinn et al. 2008 ; Silva de
Melo et al. 2005). Nevertheless, D9-THC no longer in-
duced analgesia at this stage of treatment, excluding
nociceptive interference with the aversive nature of
the electric footshock, and any locomotor effects were
controlled for in the statistical analysis. CBD did not
affect spontaneous alternation in the Y-maze nor
latency to enter the dark chamber in the PA test. These
results, combined with previous observations that
acute CBD had no effect in the radial arm maze
(Lichtman et al. 1995) and that CBD-rich cannabis
extracts had no effect in the Morris water maze
(Fadda et al. 2006), suggest that CBD does not disrupt
memory.
In conclusion, using a comprehensive behavioural
phenotyping strategy in order to capture a number
of features associated with schizophrenia and anxiety
we provide the first report that chronic CBD facilitates
sensorimotor gating, exerts anxiolytic-like effects
and attenuates Dex-induced hyperlocomotion in
C57BL/6JArc mice. Meanwhile, acute, but not chronic,
D9-THC facilitates PPI. The chronic onset of the CBD
effects and their complex dose-dependency are novel
findings that raise intriguing avenues for further
studies of its therapeutic potential. In particular, in-
vestigations using specific behavioural models of
schizophrenia, particularly in genetic mouse models,
will be useful in the future.
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